Search results

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Result type

Technology appraisal guidance

Last updated

2 July 2021

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.

Result type

Technology appraisal guidance

Published

22 June 2016

This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

years. You also need to think about your age, your health overall and what matters most to you over that time. Things to check: : Do you...

This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.

Result type

NICE guideline

Last updated

8 September 2023

Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

Result type

Technology appraisal guidance

Published

28 June 2017

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

Result type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.

Result type

Technology appraisal guidance

Last updated

27 November 2013

This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

and risks of each option? : Are you clear about which benefits and risks matter most to you? : Do you have enough support and advice to...

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Result type

Technology appraisal guidance

Published

18 February 2016

Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

Result type

Technology appraisal guidance

Published

12 July 2017

This guideline covers how to improve the physical environment to encourage and support physical activity. The aim is to increase the general population’s physical activity levels.

Result type

NICE guideline

Published

22 March 2018